ArticleScientific reports2026
In silico design of a multiepitope vaccine against antibiotic drug-resistant Acinetobacter baumannii.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Acinetobacter baumannii, a member of the ESKAPE pathogens, causes approximately 722,000 infections annually and is notorious for rapidly developing resistance to multiple antibiotics, resulting in poor clinical outcomes. Due to the rapid emergence of drug-resistant strains and limited effective treatments, the World Health Organization has listed A. baumannii as a top-priority pathogen for vaccine development, highlighting the urgent need for novel therapeutic strategies. In this study, we employed an in silico approach to design a multiepitope vaccine (MEV) targeting multidrug-resistant strains by analyzing RNA-seq data from meropenem-resistant isolates. The vaccine non-toxicity, probably antigenic, and non-allergenic nature was predicated via ToxinPred, VaxiJen v2.0, and AllerTOP v2.0 tools. CTL and HTL epitope prediction was carried out using NetMHCpan and NetMHCIIpan respectively. PEP-FOLD3.5 server predicted T-cell epitopes 3D structure. Molecular docking of the modeled epitopes into the MHC binding grooves was performed using the HADDOCK 2.4 web server for strong binding interactions. MD simulations were carried out using GROMACS version 2021.4 for the MEV stability and PCA was performed to identify dominant conformational states during the simulation. C-ImmSim server was used for the simulation of immune response. RNA-seq analysis from meropenem resistant A. baumannii strains, we identified 1,240 significantly upregulated genes linked to resistance mechanisms. From 156 non-homologous proteins, 12 highly conserved, non-allergenic antigenic proteins were selected to predict 12 CTL and 7 HTL epitopes with strong HLA-binding affinity and immunogenic potential. Molecular docking and dynamics simulations confirmed stable epitope-MHC interactions and structural stability of the 335-amino-acid MEV construct, while immune simulations indicated robust activation of innate and adaptive responses. This in silico study lays a promising foundation for vaccine development against A. baumannii and provides a critical step toward future in vitro and in vivo validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.